Chemomab Therapeutics (CMMB) Stock Price, News & Analysis

Company Overview

Chemomab Therapeutics Ltd. is a clinical-stage biotechnology company focused on developing therapies for chronic inflammatory and fibrotic diseases. The company’s research is centered on CCL24, a chemokine believed to contribute to inflammation, fibrosis and tissue damage across several disease areas.

Chemomab’s lead product candidate is CM-101, a proprietary monoclonal antibody designed to block CCL24 activity. The therapy has been evaluated in clinical studies for conditions including primary sclerosing cholangitis, a progressive liver disease, and systemic sclerosis, an autoimmune disorder that can cause widespread fibrosis. CM-101 remains an investigational product and has not been approved for commercial use.

Founded in Israel, Chemomab operates as an international biotechnology company serving the global biopharmaceutical and clinical research markets. The company is led by Chief Executive Officer Dr. Adi Zuloff-Shani and is listed on the Nasdaq Capital Market under the symbol CMMB.

Key Stats

• Today's Range: $1.37 to $1.47
• 50-Day Range: $1.19 to $2.83
• 52-Week Range: $1.05 to $3.50
• Volume: 12,203 shs
• Average Volume: 150,403 shs
• Market Capitalization: $10.01 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Reduce

Chemomab Therapeutics Stock Analysis - MarketRank™

Chemomab Therapeutics scored higher than 28% of companies evaluated by MarketBeat, and ranked 783rd out of 883 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.0 / 5
• Analyst Rating: Reduce

Consensus Rating

Chemomab Therapeutics has received a consensus rating of Reduce. The company's average rating score is 1.50, and is based on no strong buy ratings, no buy ratings, 1 hold rating, and 1 sell rating.

Amount of Analyst Coverage

Chemomab Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Chemomab Therapeutics is -0.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Chemomab Therapeutics is -0.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Chemomab Therapeutics has a P/B Ratio of 0.69. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.17% of the float of Chemomab Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Chemomab Therapeutics has a short interest ratio ("days to cover") of 0.05, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Chemomab Therapeutics has recently decreased by 87.13%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Chemomab Therapeutics does not currently pay a dividend.

Dividend Growth

Chemomab Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 2.1 / 5
• News Sentiment: 0.34

News Sentiment

Chemomab Therapeutics has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Chemomab Therapeutics this week, compared to 1 article on an average week.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Chemomab Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $6,516.00 in company stock.

Percentage Held by Insiders

11.91% of the stock of Chemomab Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

46.05% of the stock of Chemomab Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/20/2026
• Today: 10/10/2026
• Next Earnings (Estimated): 11/06/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:CMMB
• CIK: 1534248
• Web: www.chemomab.com
• Phone: 972-77-331-0156
• Fax: N/A
• Employees: 12
• Year Founded: 2010

Profitability

• EPS (Trailing Twelve Months): ($2.13)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$8.99 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -92.14%
• Return on Assets: -82.05%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.41
• Quick Ratio: 6.41

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.00 per share
• Price / Book: 0.69

Miscellaneous

• Outstanding Shares: 7,250,000
• Free Float: 6,383,000
• Market Cap: $10.01 million
• Optionable: Not Optionable
• Beta: 0.74